Methods: International, multicenter, retrospective, observational study. Outcomes presented are patient characteristics, reason for PP initiation and hospitalization data. Results: 84 patients were analyzed: Mean age (years) at first psychotic episode was 23.8(SD2.6), 23.9(SD2.6) at first antipsychotic treatment and 24.1(SD2.7, range 19-29) at PP initiation. Time between first antipsychotic treatment and PP initiation was 4.8(SD3.4, range 0-12) months. At PP initiation 42.9% of patients were in hospital, primarily for the management of the first episode/relapse (97.2%). Reason for PP initiation was: LAT favored over oral treatment for relapse prevention (56%), partial/non adherence with previous oral medication (20.0%), convenience (15.5%) or limited access to health care systems (2.4%). Mean time (days) between admission and initiation of PP, and between initiation of PP and discharge from hospital was 28.8(SD23.0) and 23.2(SD24.5), respectively. 96.4% of patients were not hospitalized during the 12-month PP treatment period. 3/84 patients (3.6%) had a single hospitalization of 15.7(SD 8.1) days for management of episode/relapse. Conclusions: In this young, newly diagnosed schizophrenia population the number of hospitalizations following PP initiation was low. Main reason to initiate PP was clinicians favoring LAT over oral antipsychotic treatment for relapse prevention or due to partial/non adherence with previous oral treatment.
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Tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate in patients hospitalized for an exacerbation of schizophrenia 
Abstract
Objective: To explore tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate (PP) in adult patients hospitalized with an exacerbation of schizophrenia. Methods: International 6-week prospective open-label noninterventional study. Outcome parameters were changes in Brief Psychiatric Rating Scale (BPRS) total score, Clinical Global Impression-Severity Scale (CGI-S), Personal and Social Performance Scale (PSP), treatment satisfaction (Medication Satisfaction Questionnaire (MSQ)), Extrapyramidal Symptom Rating Scale (ESRS) scores and treatment-emergent adverse events (TEAEs) from baseline to last-observation-carried-forward endpoint. Results: 367 patients (65.9% male, mean age (±SD) 39.8 ± 12.1 years, 85.8% paranoid schizophrenia) were documented. 91.6% of patients completed the 6-week observation period. Most frequent reasons for early discontinuation were loss to follow-up (2.7%) and withdrawal of consent (1.6%). The recommended PP initiation regimen (150 mg eq on day 1 and 100 mg eq on day 8, both in the deltoid muscle) was used in 88.8% of subjects. Mean time from hospital admission to initiation of PP was 9.4 ± 7.7 days. Mean baseline BPRS total score of 50.2 ± 13.6 improved by -6.5 ± 8.6 at day 8 and by -19.3 ± 12.6 from baseline to endpoint; 95% confidence interval [CI]-20.7;-18.0; both p<0.0001. At endpoint, 93.6% of patients were rated as improved in CGI-S. Functioning in PSP significantly improved from 49.4 ± 14.7 at baseline by 14.3 ± 12.4 at endpoint (95% CI 12.9;15.8, p<0.0001). Mean ESRS total score significantly decreased from 3.7 ± 5.9 at baseline to 2.0 ± 4.7 at endpoint (p<0.0001). 6.0% of patients were very or extremely satisfied with their previous antipsychotic medication at baseline, which increased to 46.1% with PP at endpoint. TEAEs reported in ≥2% of patients were tremor (2.5%) and schizophrenia (2.2%). Conclusions: These data support results from previous randomized controlled and pragmatic studies that flexibly dosed paliperidone palmitate is well tolerated and associated with an early and clinically meaningful treatment response and functional improvement in patients hospitalized for an exacerbation of schizophrenia. Abstract Background: Reliable biology indicators for stress reaction and psychopathology are valuable markers for both psychological research and clinical practice. Recently, the measurement of salivary alpha-amylase (sAA) was introduced as a non-invasive and more convenience protocol. Several studies showed the high sensitivity of sAA level in various mental disorders, unfortunately there still no data on how the level of sAA in naïve-drugs of schizophrenia patients. Objective: To determine whether sAA level could be as potential biomarker for therapeutic response in schizophrenia patients. Methods: Using the cohort study, we collected 30 samples that met the inclusion criteria and 30 normal control samples.sAA level and PANSS score were taken 5 times at baseline, 3 days after treatment of antipsychotics, 5 days after treatment, 7 days, and 14 days after treatment of antipsychotics. Results: Schizophrenia patients showed significant higher sAA levels compared to normal control group. sAA levels showed significant decline in correlation with the improvement of PANSS score within 2 weeks of antipsychotics therapy. Conclusion: The measurement of sAA levels can be used as potential biomarker of therapeutic response in schizophrenia patients. Key word: schizophrenia, naïve-drugs, PANSS, sAA, antipsychotic purified using the Qiagen RNeasy kit. The samples were hybridised to an Agilent SurePrint G3 Rat Gene Expression microarray. Using JMP Genomics 6.1, quality controls were checked and the expression data analyzed to identify genes with different expression profiles. The genes with different profiles were imported into Ingenuity Pathway Analysis to identify pathways affected by ovariectomy and/or estrogen treatment.
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Ovariectomy significantly altered the expression profiles of 145 genes, while estrogen treatment altered the expression profiles of 332 genes. Compared to ovariectomised rats, estrogen-treated rats showed changes in gene expression patterns predicted to affect the activity of translation initiation and elongation (p<0.001) as well as the downstream effects of the master regulator, mechanistic target of rapamycin (mTOR; p=0.002).
Importantly, while there was some overlap in altered expression profiles between the ovariectomised animals and those receiving estrogen, these results highlight that removal of sex steroids by ovariectomy substantially differs from estrogen treatment. These data suggest that the effects on translation and mTOR, combined with the effect of estrogen at estrogen responsive elements will have profound and wide-ranging effects in the frontal cortex. This supports the concept that sex steroids play a role on modulating pathways associated with psychosis and schizophrenia, including several neurotransmitter systems (e.g. dopamine, serotonin, noradrenaline, glutamate). 
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BQCA Allosteric Modulation of [3H]NMS Binding to Human Cortex is Reduced in a Subgroup of Schizophrenia and Modulation by Divalent Cations
Abstract
Muscarinic M 1 receptor (CHRM1) positive allosteric modulators represent a promising approach to treating the cognitive deficits of schizophrenia. Hence, we decided to extend studies using cloned receptors and animal models to study CHRM1 ortho-and allosteric binding in human cortex. Therefore, we measured the displacement of [ 3 H]NMS(0.13nM) with acetylcholine(0-1mM) in the presence of BQCA (positive allosteric modulator: 0-3µM) using tissue from muscarinic receptor deficit schizophrenia (MRDS) subjects (defined by a marked loss in [ 3 H]pirenzepine binding to cortical CHRM1 (~75)), other schizophrenia subjects, and non-psychiatric control subjects. This is a measure of the response of CHRM1 to positive allosteric modulation. CHRM binding sites have been shown to be ion dependent and hence we repeated our experiments using cortex from subjects without a psychiatric illness and [ (10mg/ml). As with cloned CHRM1, BQCA increases the affinity of the CHRM1 orthosteric site for acetylcholine in human cortex (logIC 50 : 0µM BQCA=−4.95, 0.3μM BQCA=−5.50, and 3.0μM BQCA=−6.21). The effect of BQCA was reduced in MRDS subjects (p<0.01; Cohen's d=−0.948), but not of sufficient magnitude to suggest allosteric modulators will not elicit a response in MRDS subjects. Zn 2+ reduced specific [
